Skip to content

Study · Observational study · n = 58,333 · 2025

5 results

Semaglutide and Tirzepatide in Patients With Heart Failure With Preserved Ejection Fraction.

Krüger N, Schneeweiss S, Fuse K, Matseyko S, Sreedhara SK, Hahn G, Schunkert H, Wang SV

JAMA1 Oct 2025Cited by 43 (Europe PMC)

PMID40886075 (opens in a new tab)PMCIDPMC12400167 (opens in a new tab)DOI10.1001/jama.2025.14092 (opens in a new tab)PepBankPUB-40886075
Source linkPubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanObservational studyEfficacy outcome

    In patients with cardiometabolic HFpEF, semaglutide initiation was associated with a lower risk of heart failure hospitalization or all-cause mortality than sitagliptin (HR 0.58).

    In plain wordsIn people with heart failure and obesity or diabetes, those starting semaglutide had fewer heart failure hospital stays or deaths than those starting sitagliptin.

    Peptide
    Semaglutide
    Outcome
    DecreaseHospitalization for heart failure or all-cause mortality
    Study

    n = 58,333

    Comparator
    Sitagliptin (placebo proxy)
    Analysis
    Primary
    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    Dose not stated

    Measurements

    HR
    0.58 ratio
    semaglutide vs sitagliptin

    Source sentences

    Summary
    Initiators of semaglutide (HR, 0.58 [95% CI, 0.51-0.65]) and tirzepatide (HR, 0.42 [95% CI, 0.31-0.57]) had substantially lower risk of the primary end point compared with sitagliptin.
    2 context sentences
    Summary · context
    Five cohort studies using national US health care claims data from 2018 to 2024.
    Summary · context
    New use of semaglutide, tirzepatide, or sitagliptin as a placebo proxy.
  2. 02HumanObservational studyEfficacy outcome

    In patients with cardiometabolic HFpEF, tirzepatide was not associated with a meaningfully lower risk of the primary composite end point than semaglutide (HR 0.86, 95% CI 0.70-1.06).

    In plain wordsIn people with heart failure and obesity or diabetes, tirzepatide did not clearly lower heart failure hospital stays or deaths more than semaglutide.

    Peptide
    Tirzepatide
    Outcome
    No significant changeHospitalization for heart failure or all-cause mortality, tirzepatide vs semaglutide
    Study

    n = 28,100

    Comparator
    Semaglutide
    Analysis
    Primary
    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    Dose not stated

    Measurements

    HR
    0.86 ratio
    tirzepatide vs semaglutide

    Source sentences

    Summary
    Tirzepatide had no meaningfully lowered risk compared with semaglutide (HR, 0.86 [95% CI, 0.70-1.06]).
    2 context sentences
    Summary · context
    Five cohort studies using national US health care claims data from 2018 to 2024.
    Summary · context
    New use of semaglutide, tirzepatide, or sitagliptin as a placebo proxy.
  3. 03HumanObservational studyEfficacy outcome

    In patients with cardiometabolic HFpEF, tirzepatide initiation was associated with a lower risk of heart failure hospitalization or all-cause mortality than sitagliptin (HR 0.42).

    In plain wordsIn people with heart failure and obesity or diabetes, those starting tirzepatide had fewer heart failure hospital stays or deaths than those starting sitagliptin.

    Peptide
    Tirzepatide
    Outcome
    DecreaseHospitalization for heart failure or all-cause mortality
    Study

    n = 11,257

    Comparator
    Sitagliptin (placebo proxy)
    Analysis
    Primary
    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    Dose not stated

    Measurements

    HR
    0.42 ratio
    tirzepatide vs sitagliptin

    Source sentences

    Summary
    Initiators of semaglutide (HR, 0.58 [95% CI, 0.51-0.65]) and tirzepatide (HR, 0.42 [95% CI, 0.31-0.57]) had substantially lower risk of the primary end point compared with sitagliptin.
    2 context sentences
    Summary · context
    Five cohort studies using national US health care claims data from 2018 to 2024.
    Summary · context
    New use of semaglutide, tirzepatide, or sitagliptin as a placebo proxy.
  4. 04HumanObservational studySafety outcome

    In patients with cardiometabolic HFpEF, no substantially increased risk was observed for select safety end points with semaglutide.

    In plain wordsIn people with heart failure and obesity or diabetes, semaglutide showed no clearly higher risk for the safety outcomes checked.

    Peptide
    Semaglutide
    Outcome
    No significant changeSelect safety end points
    Study

    n: not reported in source

    Outcome group
    Adverse events · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    No substantially increased risk was observed for select safety end points.
    2 context sentences
    Summary · context
    Five cohort studies using national US health care claims data from 2018 to 2024.
    Summary · context
    New use of semaglutide, tirzepatide, or sitagliptin as a placebo proxy.
  5. 05HumanObservational studySafety outcome

    In patients with cardiometabolic HFpEF, no substantially increased risk was observed for select safety end points with tirzepatide.

    In plain wordsIn people with heart failure and obesity or diabetes, tirzepatide showed no clearly higher risk for the safety outcomes checked.

    Peptide
    Tirzepatide
    Outcome
    No significant changeSelect safety end points
    Study

    n: not reported in source

    Outcome group
    Adverse events · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    No substantially increased risk was observed for select safety end points.
    2 context sentences
    Summary · context
    Five cohort studies using national US health care claims data from 2018 to 2024.
    Summary · context
    New use of semaglutide, tirzepatide, or sitagliptin as a placebo proxy.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials4

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

4 trials · 1 not yet recruiting · 3 completed · source ClinicalTrials.gov (opens in a new tab)

Not yet recruitingPhase 2/3NCT07734792

Tirzepatide in Thrombectomy-Treated Acute Ischemic Stroke: A Randomized Trial

yifang zhun = 726est. 20 Sept 2026 to est. 31 Jul 2028

Acute Ischemic Stroke (AIS)

Trial pageClinicalTrials.govUpdated 1 Oct 2026
CompletedPhase not statedNCT06914102

Emulation of the STEP-HFpEF DM Heart Failure Trial in Healthcare Claims Data

Brigham and Women's Hospitaln = 58,38714 Jan 2025 to 1 Jun 2025

Diabetes Mellitus, Type 2 · HFpEF - Heart Failure With Preserved Ejection Fraction

Trial pageClinicalTrials.govUpdated 30 Jan 2026
CompletedPhase not statedNCT06914141

Comparative Effectiveness of Tirzepatide Versus Semaglutide in Individuals With Heart Failure With Preserved Ejection Fraction

Brigham and Women's Hospitaln = 28,11814 Jan 2025 to 1 Jun 2025

Diabetes Mellitus, Type 2 · HFpEF - Heart Failure With Preserved Ejection Fraction

Trial pageClinicalTrials.govUpdated 30 Jan 2026
CompletedPhase not statedNCT06914154

Emulation of the SUMMIT Heart Failure Trial in Healthcare Claims Data

Brigham and Women's Hospitaln = 11,26514 Jan 2025 to 1 Jun 2025

Diabetes Mellitus, Type 2 · Heart Failure With Preserved Ejection Fraction (HFPEF)

Trial pageClinicalTrials.govUpdated 30 Jan 2026

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:07 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.